News

The partnership intends to discover, develop and commercialize novel therapies based on Agios’ cellular metabolism research platform. Celgene will pay Agios $200m upfront for an initial four-year research

The approval is based on overall response rate in cHL patients who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin. Opdivo

Benralizumab demonstrated significant reductions in the annual asthma exacerbation rate compared to placebo. The trials, Sirocco and Calima, assessed the safety and efficacy of two dose regimens of

Adzenys XR-ODT was approved by the U.S. Food and Drug Administration (FDA) in January for the treatment of ADHD in patients six years and older and is the

The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the

The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to

This proof-of-concept study will evaluate the effect of N91115 as add-on therapy to Kalydeco™ (ivacaftor) in adult patients who have one copy of the F508del mutation and a

Last month, lawmakers failed to approve the US Government’s request for $1.9bn in emergency funding made in February. AHF said Congress is not concerned on the mosquito-borne and

The randomized, double-blind, standard of care-controlled trial, dubbed BLAST-AHF, assessed three doses of TRV027 plus standard heart failure therapy compared to placebo plus standard therapy in 618 patients